The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).
Kiyoshi Ando
Research Funding - MSD; MSD Japan
Michinori Ogura
Research Funding - MSD Japan
Tatsuya Suzuki
Research Funding - MSD; MSD Japan
Kenichi Ishizawa
Research Funding - MSD; MSD Japan
Sung Yong Oh
Research Funding - MSD; MSD Japan
Won Seog Kim
Research Funding - MSD Japan
Yoshinobu Tanaka
No relevant relationships to disclose
Takashi Shimamoto
No relevant relationships to disclose
Kensei Tobinai
Consultant or Advisory Role - Advisory Role
Research Funding - MSD Japan